Argenx Se (ARGX) Total Current Liabilities (2015 - 2026)
Argenx Se's (ARGX) quarterly Total Current Liabilities came in at $1.6 billion in Q2 2026, down 99.85% YoY from $1041.9 billion in Q2 2025, and up 19.32% on a QoQ basis from $1.3 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Total Current Liabilities (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Total Current Liabilities data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Total Current Liabilities fell 99.85% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 99.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 97.04% from the prior year.
- Total Current Liabilities grew to $1.6 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1041.9 billion in Q2 2025 to a low of $264.6 million in Q2 2022.
- A 5-year average of $116.4 billion and a median of $499.6 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 208435.53% — and 2026, when it sank 99.85%.
- Tracing ARGX's Total Current Liabilities over 5 years: stood at $302.3 million in 2022, then soared by 39.94% to $423.0 million in 2023, then jumped by 58.38% to $669.9 million in 2024, then surged by 97.04% to $1.3 billion in 2025, then gained by 19.32% to $1.6 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.6 billion (Q2 2026), $1.3 billion (Q4 2025), and $1041.9 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | 1.31 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1,041.90 Bn |
| Dec 31, 2024 | 669.92 Bn |
| Jun 30, 2024 | 499.63 Mn |
| Dec 31, 2023 | 422.99 Mn |
| Jun 30, 2023 | 317.79 Mn |
| Dec 31, 2022 | 302.28 Bn |
| Jun 30, 2022 | 264.60 Mn |
| Dec 31, 2021 | 301.24 Bn |
| Jun 30, 2021 | 244.04 Mn |
| Dec 31, 2020 | 319.17 Bn |
| Jun 30, 2020 | 217.90 Mn |
| Dec 31, 2019 | 177.05 Mn |
| Jun 30, 2019 | 115.05 Mn |
| Dec 31, 2018 | 45.72 Mn |
| Jun 30, 2018 | 32.26 Mn |
| Dec 31, 2017 | 28.87 Mn |
| Jun 30, 2017 | 38.74 Mn |
| Dec 31, 2016 | 34.90 Mn |